Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253064 | 0.92 | MAPK14 (0.46) | MAPK14MAPK9 | |
| SCHEMBL3251945 | 0.91 | MAPK14 (0.45) | MAPK14PDE4BCDK9MAPK9CCNT1 | |
| SCHEMBL13678734 | 0.88 | LRRK2 (0.49) | MAPK14PDE4BCDK9CDK1CDK2 | |
| SCHEMBL3249333 | 0.86 | MAPK14 (0.55) | MAPK14MAPK9 | |
| SCHEMBL13678697 | 0.85 | MAPK9 (0.49) | MAPK14MAPK9 | |
| SCHEMBL3251993 | 0.84 | MAPK14 (0.47) | MAPK14CDK9MAPK9CCNT1 | |
| SCHEMBL3246016 | 0.83 | MAPK9 (0.48) | MAPK14MAPK9 | |
| SCHEMBL3252013 | 0.81 | MAPK9 (0.46) | MAPK14MAPK9 | |
| SCHEMBL13304497 | 0.80 | FGFR1 (0.47) | MAPK14 | |
| SCHEMBL3248769 | 0.80 | KDR (0.51) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | claimed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258874-A1 | PYRAZOLO-HETEROARYL COMPOUNDS | IL1R1, IL1A, IL1B | MAPK14 2463/4885PDE4B 2775/4885CDK9 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.